I
INNOVATE Biopharmaceuticals
Clinical stage biotechnology company developing novel medicines for gastroenterological and orphan disorders
About INNOVATE Biopharmaceuticals
Innovate Biopharmaceuticals is a publicly traded clinical-stage biotechnology company listed on Nasdaq under the ticker INNT. The company is dedicated to developing innovative medicines aimed at treating autoimmune and inflammatory diseases that currently lack effective treatments. Innovate's pipeline includes several promising drug candidates: Larazotide Acetate (INN 202) in Phase 3 for celiac disease (CeD) with Fast Track designation, INN 217 in preclinical stages for nonalcoholic steatohepatitis (NASH), INN 289 in preclinical stages for a subset of Crohn's disease (CD), and INN 108 in Phase 1 for mild to moderate ulcerative colitis (UC) and a gastrointestinal orphan disease in a convenient liquid formulation.
The company primarily serves patients suffering from these chronic conditions, aiming to provide them with more effective and convenient treatment options. Innovate operates in the biopharmaceutical market, focusing on areas with significant unmet medical needs. Its business model revolves around the development and commercialization of its drug candidates. Revenue generation is expected to come from the successful approval and market launch of these drugs, as well as potential partnerships and licensing agreements.
Innovate is led by a management team with extensive experience in drug development and a proven track record of bringing novel therapeutics to market. The company holds global rights to its products, supported by a robust portfolio of over 150 patents.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2016
News
Open roles
INNOVATE Biopharmaceuticals in the Raleigh ecosystem
The INNOVATE Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about INNOVATE Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See INNOVATE Biopharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

